非编码RNAs在调节癌症对托波特坎敏感性的关键重要性:系统性审查
Seyed Mostafa Rahimi1, Abouzar Bagheri2,3
1Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran.
Medical oncology (Northwood, London, England)
|September 13, 2025
概括
微RNA (miRNA) 和非编码RNA影响癌症治疗结果. 了解它们与Topotecan化疗的相互作用,可以提高癌症治疗的有效性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 癌症仍然是全球主要的死亡原因,需要改进治疗策略.
- 托波特坎是一种用于治疗各种癌症的化疗剂,但其有效性受到药物耐药性的限制.
- 微RNA (miRNA) 和其他非编码RNA是化学疗法耐药性的关键调节剂.
研究的目的:
- 系统地审查非编码RNA和Topotecan之间的相互作用机制.
- 研究这些相互作用如何调节癌症对托波特坎化疗的敏感性.
主要方法:
- 系统的文献审查遵循PRISMA指南.
- 在PubMed,Scopus和Web of Science数据库中进行全面的搜索.
- 根据预先定义的选择标准,包括11项研究.
主要成果:
- 改变非编码RNA表达,特别是miRNAs,显著影响癌症对Topotecan的敏感性.
- 这些调节效应通过直接和间接调节信号通路而发生.
- 在各种癌症类型中观察到影响,包括视网膜母细胞瘤,结肠直肠癌,乳腺癌和前列腺癌.
结论:
- 非编码RNAs,特别是miRNAs,对于确定癌细胞和对Topotecan.can的模型反应至关重要.
- 准这些RNA分子为增强Topotecan化疗功效提供了潜在的新策略.
- 对这些相互作用的进一步研究可能会导致改善各种癌症的治疗干预措施.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
7.2K
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
3.1K
相关概念视频
lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer-Critical Genes II: Tumor Suppressor Genes
9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
